World's Best Scientists 2026 revealed!
Øystein Bruserud

Øystein Bruserud

D-Index & Metrics

Immunology

D-Index
64
Citations
13193
World Ranking
2952
National Ranking
18

Øystein Bruserud publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Øystein Bruserud sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 401 publications — 81st percentile

81% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Øystein Bruserud D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Øystein Bruserud sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 64 D-Index — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Øystein Bruserud is affiliated with the University of Bergen in Norway and has contributed extensively to the fields of medicine, biochemistry, genetics, and molecular biology. Their research prominently focuses on hematology, molecular biology, immunology, oncology, and cancer research.

The scientist's primary areas of study include acute myeloid leukemia (AML) research, hematopoietic stem cell transplantation, histone deacetylase inhibitors research, retinoids in leukemia and cellular processes, immune cell function and interaction, protein degradation and inhibitors, and hematological disorders and diagnostics.

Øystein Bruserud has authored several recent papers, demonstrating a focus on inflammatory parameters in cancer and acute myeloid leukemia. Notable publications include:

  • Combined C-Reactive Protein and Novel Inflammatory Parameters as a Predictor in Cancer-What Can We Learn from the Hematological Experience?, 2020, Cancers

Frequent coauthors in their research collaborations include:

  • Håkon Reikvam
  • Tor Henrik Anderson Tvedt
  • Frode Selheim
  • Maria Hernandez-Valladares
  • Elise Aasebø

Øystein Bruserud's work is regularly published in scientific journals that focus on clinical and molecular aspects of oncology and hematology. The most frequent publication venues are:

  • Cancers
  • Journal of Clinical Medicine
  • Cells
  • International Journal of Molecular Sciences
  • Tidsskrift for Den norske legeforening

Their research addresses complex biological mechanisms underlying hematological malignancies and cancer progression, often integrating clinical implications. Topics like acute myeloid leukemia and immune cell function reflect a multidisciplinary approach combining molecular biology and clinical medicine.

Best Publications

  • Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells

    Jonathan M Irish;Randi Hovland;Peter O Krutzik;Omar D Perez

  • SIRT1 Activation by a c-MYC Oncogenic Network Promotes the Maintenance and Drug Resistance of Human FLT3-ITD Acute Myeloid Leukemia Stem Cells

    Ling Li;Tereza Osdal;Yinwei Ho;Sookhee Chun

  • Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells

    O. Bruserud;C. Stapnes;E. Ersvær;B. T. Gjertsen

  • A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life

    Jan Samuelsson;Hans Hasselbalch;Oystein Bruserud;Snezana Temerinac

  • Acute Myeloid Leukemia with the t(8;21) Translocation: Clinical Consequences and Biological Implications

    Håkon Reikvam;Kimberley Joanne Hatfield;Astrid Olsnes Kittang;Astrid Olsnes Kittang;Randi Hovland

  • Cryopreserving human peripheral blood progenitor cells with 5-percent rather than 10-percent DMSO results in less apoptosis and necrosis in CD34+ cells.

    Jenny Foss Abrahamsen;Anne M. Bakken;Øystein Bruserud

  • Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells.

    Øystein Bruserud;Anita Ryningen;Astrid Marta Olsnes;Laila Stordrange

  • The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells.

    Camilla Stapnes;Anne P. Døskeland;Kimberley Hatfield;Elisabeth Ersvær

  • Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities

    Øystein Bruserud;Randi Hovland;Line Wergeland;Tien-Sheng Huang

  • Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome

    Astrid Olsnes Kittang;Shahram Kordasti;Kristoffer Evebø Sand;Benedetta Costantini

  • Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia

    Mika Kontro;Heikki Kuusanmäki;Samuli Eldfors;T Burmeister

  • Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents

    Hanne Kristin Fredly;Bjørn Tore Gjertsen;Bjørn Tore Gjertsen;Øystein Bruserud;Øystein Bruserud

  • A Distinct p53 Protein Isoform Signature Reflects the Onset of Induction Chemotherapy for Acute Myeloid Leukemia

    Nina Anensen;Anne Margrete Oyan;Jean-Christophe Bourdon;Karl Henning Kalland

  • Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts

    Øystein Bruserud;Anita Ryningen;Line Wergeland;Nils Idar Glenjen

  • The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia.

    K. J. Hatfield;H. Reikvam;O. Bruserud

  • In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage.

    Torunn Ø Apelseth;Øystein Bruserud;Tore Wentzel-Larsen;Anne M Bakken

  • The role of arginine and arginine-metabolizing enzymes during Giardia – host cell interactions in vitro

    Britta Stadelmann;Kurt Hanevik;Kurt Hanevik;Mattias K Andersson;Oystein Bruserud

  • Animal models of acute myelogenous leukaemia - development, application and future perspectives.

    E McCormack;O Bruserud;O Bruserud;B T Gjertsen;B T Gjertsen

  • Therapeutic targeting the cell division cycle 25 (CDC25) phosphatases in human acute myeloid leukemia--the possibility to target several kinases through inhibition of the various CDC25 isoforms.

    Annette K. Brenner;Håkon Reikvam;Antonio Lavecchia;Øystein Bruserud

  • New strategies for the treatment of acute myelogenous leukemia: differentiation induction--present use and future possibilities.

    Øystein Bruserud;Bjørn Tore Gjertsen

  • Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis

    Gro Gausdal;Anita Wergeland;Jørn Skavland;Eric Nguyen;Eric Nguyen

Frequent Co-Authors

Bjørn Tore Gjertsen
Bjørn Tore Gjertsen Haukeland University Hospital
Stein Ove Døskeland
Stein Ove Døskeland University of Bergen
Graham Pawelec
Graham Pawelec University of Tübingen
Philippe Lassalle
Philippe Lassalle Institut Pasteur
Janet M. Lord
Janet M. Lord University of Birmingham
Peter B. Ernst
Peter B. Ernst University of California, San Diego
Tore Wentzel-Larsen
Tore Wentzel-Larsen Norwegian Centre for Violence and Traumatic Stress Studies
Heike L. Pahl
Heike L. Pahl University of Freiburg
Nina Langeland
Nina Langeland Haukeland University Hospital
Staffan G. Svärd
Staffan G. Svärd Uppsala University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in expanding their career options alongside Immunology, nursing offers diverse opportunities. Many programs cater to individuals without a nursing background, such as online ADN programs for non nurses, which provide a flexible path to become a registered nurse.

Accelerated routes are also available. If you already hold a bachelor’s degree in another field, accelerated BSN programs for non nurses allow you to earn a Bachelor of Science in Nursing quickly and enter the workforce faster.

For those seeking entry-level positions, accredited LPN programs easy to get into can be an excellent starting point. These programs are designed to be accessible and provide essential skills for practical nursing roles.

Advanced practice nurses can also benefit from easier admission pathways. The easiest NP programs to get into are ideal for nurses looking to specialize further and take on leadership roles in healthcare.

Each of these educational tracks aligns well with careers intersecting immunology, healthcare, and patient care, offering multiple avenues for growth and specialization.

Best Scientists Citing Øystein Bruserud

Trending Scientists

Recently Published Articles